Literature DB >> 31084924

Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease.

Ceri Rowe1, Alice J Sitch2, Jonathan Barratt3, Elizabeth A Brettell4, Paul Cockwell5, R Neil Dalton6, Jon J Deeks7, Gillian Eaglestone8, Tracy Pellatt-Higgins9, Philip A Kalra10, Kamlesh Khunti11, Fiona C Loud12, Frances S Morris8, Ryan S Ottridge4, Paul E Stevens8, Claire C Sharpe13, Andrew J Sutton14, Maarten W Taal15, Edmund J Lamb16.   

Abstract

When assessing changes in glomerular filtration rate (GFR) it is important to differentiate pathological change from intrinsic biological and analytical variation. GFR is measured using complex reference methods (e.g., iohexol clearance). In clinical practice measurement of creatinine and cystatin C are used in the Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equations to provide estimated GFR. Here we studied the biological variability of measured and estimated GFR in twenty nephrology outpatients (10 male, 10 female; median age 71, range 50-80 years) with moderate CKD (GFR 30-59 ml/min per 1.73 m2). Patients underwent weekly GFR measurement by iohexol clearance over four consecutive weeks. Simultaneously, GFR was estimated using the MDRD, CKD-EPIcreatinine, CKD-EPIcystatinC and CKD-EPIcreatinine+cystatinC equations. Within-subject biological variation expressed as a percentage [95% confidence interval] for the MDRD (5.0% [4.3-6.1]), CKD-EPIcreatinine (5.3% [4.5-6.4]), CKD-EPIcystatinC (5.3% [4.5-6.5]), and CKD-EPIcreatinine+cystatinC (5.0% [4.3-6.2]) equations were broadly equivalent. The within-subject biological variation for MDRD and CKD- EPIcreatinine+cystatinC estimated GFR were each significantly lower than that of the measured GFR (6.7% [5.6-8.2]). Reference change values, the point at which a true change in a biomarker in an individual can be inferred to have occurred with 95% probability were calculated. By the MDRD equation, positive and negative reference change values were 15.1% and 13.1% respectively. If an individual's baseline MDRD estimated GFR (ml/min per 1.73 m2) was 59, significant increases or decreases would be to values over 68 or under 51 respectively. Within-subject variability of estimated GFR was lower than measured GFR. Reference change values can be used to understand GFR changes in clinical practice. Thus, estimates of GFR are at least as reliable as measured GFR for monitoring patients over time. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic Kidney Disease Epidemiology Collaboration; Modification of Diet in Renal Disease Study; biological variation; creatinine; cystatin C; glomerular filtration rate; iohexol; kidney disease

Mesh:

Year:  2019        PMID: 31084924     DOI: 10.1016/j.kint.2019.02.021

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

Review 1.  [Clinical implications of the estimated glomerular filtration rate].

Authors:  Christian Weingart; Gerhard H Wirnsberger
Journal:  Z Gerontol Geriatr       Date:  2021-01-26       Impact factor: 1.281

2.  Cystatin C as a biomarker of chronic kidney disease: latest developments.

Authors:  Stefanie W Benoit; Eileen A Ciccia; Prasad Devarajan
Journal:  Expert Rev Mol Diagn       Date:  2020-05-25       Impact factor: 5.225

Review 3.  GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.

Authors:  Blaithin A McMahon; Mitchell H Rosner
Journal:  Kidney360       Date:  2020-01-13

4.  Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects.

Authors:  Sebastian Strubl; Simon Oehm; Jacob A Torres; Franziska Grundmann; Jazmine Haratani; Morgan Decker; Sabrina Vuong; Amrit Kaur Bhandal; Nils Methot; Rhianna Haynie-Cion; Franziska Meyer; Florian Siedek; Uwe Korst; Roman-Ulrich Müller; Thomas Weimbs
Journal:  Clin Kidney J       Date:  2021-09-13

5.  A Long-term Estimated Glomerular Filtration Rate Plot Analysis Permits the Accurate Assessment of a Decline in the Renal Function by Minimizing the Influence of Estimated Glomerular Filtration Rate Fluctuations.

Authors:  Jun Nakazawa; Satoru Yamanaka; Shohei Yoshida; Mamoru Yoshibayashi; Miho Yoshioka; Takamasa Ito; Shin-Ichi Araki; Shinji Kume; Hiroshi Maegawa
Journal:  Intern Med       Date:  2022-06-15       Impact factor: 1.282

Review 6.  Measured and estimated glomerular filtration rate: current status and future directions.

Authors:  Andrew S Levey; Josef Coresh; Hocine Tighiouart; Tom Greene; Lesley A Inker
Journal:  Nat Rev Nephrol       Date:  2019-09-16       Impact factor: 28.314

7.  Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.

Authors:  Dietrich Rothenbacher; Martin Rehm; Licia Iacoviello; Simona Costanzo; Hugh Tunstall-Pedoe; Jill J F Belch; Stefan Söderberg; Johan Hultdin; Veikko Salomaa; Pekka Jousilahti; Allan Linneberg; Susana Sans; Teresa Padró; Barbara Thorand; Christa Meisinger; Frank Kee; Amy Jayne McKnight; Tarja Palosaari; Kari Kuulasmaa; Christoph Waldeyer; Tanja Zeller; Stefan Blankenberg; Wolfgang Koenig
Journal:  BMC Med       Date:  2020-11-09       Impact factor: 8.775

8.  Avoiding insufficient therapies and overdosing with co-reporting eGFRs (estimated glomerular filtration rate) for personalized drug therapy and improved outcomes - a simulation of the financial benefits.

Authors:  Adrian Hoenle; Karin Johanna Haase; Sebastian Maus; Manfred Hofmann; Matthias Orth
Journal:  EJIFCC       Date:  2021-02-28

9.  How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy.

Authors:  Brian J Nankivell; Lachlan F J Nankivell; Grahame J Elder; Simon M Gruenewald
Journal:  EClinicalMedicine       Date:  2020-12-01

10.  GFR Estimation After Cystatin C Reference Material Change.

Authors:  Stefanie W Benoit; Thelma Kathman; Jay Patel; Melinda Stegman; Cristina Cobb; Jonathan Hoehn; Prasad Devarajan; Edward J Nehus
Journal:  Kidney Int Rep       Date:  2020-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.